Paolo Tarantino: EBCTCG analysis of breast cancer patients outcomes over two decades
Paolo Tarantino shared on X:
“What is the actual impact of breast cancer clinical research on patients outcomes? Proud to share our editorial just published in The Lancet, where Sara Tolaney and I discuss the results of an EBCTCG analysis of 151 trials which analyzed BC patients outcomes over two decades.
After correction for tumor features and treatments, patients diagnosed after 2000 were found to have 20-25% lower rate of distant recurrence than those diagnosed in the 90s, highlighting a steady progress in patients management and outcomes.
Link to the new EBCTCG meta-analysis.”
Progress in breast cancer management | The Lancet
Authors: Paolo Tarantino, Sara M Tolaney
More posts featuring Paolo Tarantino on oncodaily.com
Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023